Free Trial
NASDAQ:XERS

Xeris Biopharma Q1 2025 Earnings Report

Xeris Biopharma logo
$4.57 +0.16 (+3.63%)
As of 04:00 PM Eastern

Xeris Biopharma EPS Results

Actual EPS
N/A
Consensus EPS
-$0.07
Beat/Miss
N/A
One Year Ago EPS
N/A

Xeris Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
$57.61 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Xeris Biopharma Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

Xeris Biopharma Earnings Headlines

M.A.G.A. is Finished – This Could be even Better
You’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big change. Make America Wealthy Again (M.A.W.A).
Xeris Announces Changes to Its Board of Directors
12 Best Stocks to Invest in for a Stock Market Game
See More Xeris Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Xeris Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xeris Biopharma and other key companies, straight to your email.

About Xeris Biopharma

Xeris Biopharma (NASDAQ:XERS), a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

View Xeris Biopharma Profile

More Earnings Resources from MarketBeat